NCT01951027View on ClinicalTrials.gov

Phase I Study GX-G3 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

53

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

December 31, 2014

Conditions

Healthy

Interventions

DRUG

GX-G3 12.5 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 25 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 50 μg/kg or Placebo

Single SC injection

DRUG

GX-G3 100 μg/kg or Placebo

Single SC injection

Trial Locations (1)

301-721

Chungnam National University Hospital, Jung-gu

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Genexine, Inc.

INDUSTRY

NCT01951027 - Phase I Study GX-G3 in Healthy Subjects | Biotech Hunter | Biotech Hunter